ArticleFrontiers in immunology2023
Breast cancer associated CD169
Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- B cells in cancer: functions, mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2026Review
- Tumor-distant pulmonary immune landscapes are associated with postoperative outcomes in non-small cell lung cancer.Translational lung cancer research · 2026Article
- Decoding the breast cancer microenvironment by spatial multi-omics: from architecture to clinical translation.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Metabolic regulation of tumor-associated macrophage function and immunotherapy in cancer.Cancer biology & medicine · 2026Review
- CD169-positive macrophages in lymph nodes and the tumor microenvironment: harnessing their biology for clinical diagnosis and anticancer therapeutic strategies.Frontiers in immunology · 2026Review
- Pleiotropic and multicellular roles of lymphotoxin beta receptor in solid tumor immunity and therapeutic targeting.Frontiers in immunology · 2026Review
- Site-dependent differences and common features of lymph node architecture, with special reference to the distribution of nodal dendritic cells and macrophages: a cadaveric study.Anatomy & cell biology · 2025Article
- Topohistology of dendritic cells and macrophages in the distal and proximal nodes along the lymph flow from the lung.Journal of anatomy · 2025Article
- Altered immune signatures in breast cancer lymph nodes with metastases revealed by spatial proteome analyses.Journal of translational medicine · 2025Article
- Exploring CD169Vaccines · 2025Review
- Dissecting Tertiary Lymphoid Structures in Cancer: Maturation, Localization and Density.Theranostics · 2025Review
- The dual immunomodulatory role of B cells in tumorigenesis: mechanisms, microenvironment crosstalk, and therapeutic implications.Frontiers in immunology · 2025Review
- Tissue-Resident Macrophages in Cancer: Friend or Foe?Cancer medicine · 2024Review
- Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2024Review
- Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy.Journal for immunotherapy of cancer · 2024Article
- Biomaterials' enhancement of immunotherapy for breast cancer by targeting functional cells in the tumor micro-environment.Frontiers in immunology · 2024Review
- Role of tertiary lymphoid structures and B cells in clinical immunotherapy of gastric cancer.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD169
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.